Browse PCBP2

Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Loosely bound in the nucleus. May shuttle between the nucleus and the cytoplasm.
Domain PF00013 KH domain
Function

Single-stranded nucleic acid binding protein that binds preferentially to oligo dC. Major cellular poly(rC)-binding protein. Binds also poly(rU). Negatively regulates cellular antiviral responses mediated by MAVS signaling (PubMed:19881509). It acts as an adapter between MAVS and the E3 ubiquitin ligase ITCH, therefore triggering MAVS ubiquitination and degradation (PubMed:19881509). ; FUNCTION: (Microbial infection) In case of infection by poliovirus, binds to the viral internal ribosome entry site (IRES) and stimulates the IRES-mediated translation (PubMed:12414943, PubMed:24371074). Also plays a role in initiation of viral RNA replication in concert with the viral protein 3CD (PubMed:12414943).

> Gene Ontology
 
Biological Process GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000398 mRNA splicing, via spliceosome
GO:0001818 negative regulation of cytokine production
GO:0002181 cytoplasmic translation
GO:0002183 cytoplasmic translational initiation
GO:0002190 cap-independent translational initiation
GO:0002192 IRES-dependent translational initiation
GO:0002683 negative regulation of immune system process
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002831 regulation of response to biotic stimulus
GO:0002832 negative regulation of response to biotic stimulus
GO:0006397 mRNA processing
GO:0006413 translational initiation
GO:0008380 RNA splicing
GO:0009615 response to virus
GO:0010498 proteasomal protein catabolic process
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0019080 viral gene expression
GO:0019081 viral translation
GO:0031348 negative regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032606 type I interferon production
GO:0039694 viral RNA genome replication
GO:0039703 RNA replication
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044033 multi-organism metabolic process
GO:0048525 negative regulation of viral process
GO:0050687 negative regulation of defense response to virus
GO:0050688 regulation of defense response to virus
GO:0050792 regulation of viral process
GO:0051607 defense response to virus
GO:0075522 IRES-dependent viral translational initiation
GO:0098542 defense response to other organism
Molecular Function GO:0003697 single-stranded DNA binding
GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
GO:1990829 C-rich single-stranded DNA binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PCBP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PCBP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.72; FDR: 0.011 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PCBP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1580.402
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0180.996
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2870.906
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3840.398
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0160.995
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8510.805
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1510.771
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1550.95
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1430.958
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2210.934
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3980.924
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0840.12
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PCBP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PCBP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PCBP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PCBP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PCBP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PCBP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PCBP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPCBP2
Namepoly(rC) binding protein 2
Aliases HNRPE2; hnRNP-E2; HNRNPE2; heterogenous nuclear ribonucleoprotein E2; poly(rC)-binding protein 2; alpha-CP2; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PCBP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.